Title
L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients
Phase
Phase 2/Phase 3Lead Sponsor
Pari Pharma GmbHStudy Type
InterventionalStatus
TerminatedIndication/Condition
Bronchiolitis ObliteransIntervention/Treatment
cyclosporine ...Study Participants
130Immunosuppression is a key intervention in patients with solid organ transplant and is usually achieved by combination therapy with systemic CsA or tacrolimus with azathioprine, mycophenolate mofetil (MMF), or corticoids. However, the outcomes after lung transplantation are poor when compared with those after heart, kidney, or liver transplantation, with a survival rate of only 55% for recipients of lung transplants.
Additional application of aerosolised L-CsA should suppress T-cell activation in the lung tissue and subsequently BOS development. The overall purpose of this phase-II/III study is to obtain efficacy and safety data of L-CsA in the prevention of BOS.
Preventive therapeutic intervention by L-CsA is primarily aimed to suppress T-lymphocyte suppression and inflammatory responses and secondly to prevent fibrotic effects making it more likely to be effective in early stages of BOS. Early development of BOS, which mostly will not be diagnosed, and acute organ rejections are strongly patho-physiological associated. Prevention of the very early development of chronic rejection by L-CsA post LTX may be the ideal starting point for IMP application.
Cyclosporin for inhalation twice daily
Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
Inclusion Criteria: Patient's written informed consent Received a single lung, bilateral lung or heart/lung transplantation between 6 weeks and 26 weeks prior to first IMP administration. Male or female, 18 years of age Capable of self-administration of medications Capable of understanding the purpose and risk of the clinical trial Received the following immunosuppressive agents and dosages for maintenance therapy: Tacrolimus and Mycophenolate mofetil (MMF) 1 to 3 g/day and Prednisone or any other steroid therapy; tapered down Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration. Estimated life expectancy > 6 month Exclusion Criteria: Any previous episode of bronchiolitis obliterans (BO) or bronchiolitis obliterans syndrome (BOS) of grade 1 or higher Any active invasive bacterial, viral or fungal infection Received systemic maintenance immunosuppressive therapy other than listed in the inclusion criteria Received any systemic or topical ciclosporin A within Received any systemic or topical Rosuvastatin Current mechanical ventilation Received a lung re-transplantation Pregnant or breast feeding woman Has known hypersensitivity to ciclosporin A Has a serum creatinine value of more than 265 µmol/L (3 mg/dL) Unlikely to comply with visits, inhalation procedures or spirometric measurements Receipt of an investigational drug within 4 weeks prior to first administration of IMP Any co-existing medical condition that in the investigator's judgement Psychiatric disorders or altered mental status Patient was previously enrolled in the present clinical trial
